trending Market Intelligence /marketintelligence/en/news-insights/trending/tnnopiobfqlsqkcmmzanjw2 content esgSubNav
In This List

Assembly Biosciences names CFO, COO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Assembly Biosciences names CFO, COO

Assembly Biosciences Inc. appointed Graham Cooper as CFO and COO, effective March 8.

Cooper will be assuming the roles previously held by David Barrett, one of company's co-founders. Barrett will continue as a strategic adviser to Indiana-based Assembly.

In addition, the company appointed Helen Kim as a director.

Cooper most recently served as CFO of Receptos before its acquisition by Celgene Corp. in 2015. Kim most recently served as executive vice president of business development at Kite Pharma Inc.

Assembly Biosciences is a clinical-stage biotechnology company that develops oral therapeutics to treat hepatitis B virus infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the U.S.